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Background: In Sub-Saharan Africa cross-sectional studies report a high prevalence of abnormal lung function
indicative of chronic respiratory disease. The natural history and health impact of this abnormal lung func-
tion in low-and middle-income countries is largely unknown.
Methods: A cohort of 1481 adults representative of rural Chikwawa in Malawi were recruited in 2014 and fol-
lowed-up in 2019. Respiratory symptoms and health-related quality of life (HRQoL) were quantified. Lung
function was measured by spirometry.
Findings: 1232 (83%) adults participated; spirometry was available for 1082 (73%). Mean (SD) age 49.5 (17.0)
years, 278(23%) had ever smoked, and 724 (59%) were women. Forced expiratory volume in one second
(FEV1) declined by 53.4 ml/year (95% CI: 49.0, 57.8) and forced vital capacity (FVC) by 45.2 ml/year (95% CI:
39.2, 50.5) . Chronic airflow obstruction increased from 9.5% (7.6, 11.6%) in 2014 to 17.5% (15.3, 19.9%) in
2019. There was no change in diagnosed asthma or in spirometry consistent with asthma or restriction. Rate
of FEV1 decline was not associated with diagnosed Chronic obstructive pulmonary disease (COPD), asthma,
or spirometry consistent with asthma, COPD, or restriction. HRQoL was adversely associated with respiratory
symptoms (dyspnoea, wheeze, cough), previous tuberculosis, declining FEV1 and spirometry consistent with
asthma or restriction. These differences exceeded the minimally important difference.
Interpretation: In this cohort, the increasing prevalence of COPD is associated with the high rate of FEV1
decline and lung function deficits present before recruitment. Respiratory symptoms and sub-optimal lung
function are independently associated with reduced HRQoL.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)ences and International Public
Place, Liverpool L3 5QA, UK.
joroge).
Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
Chronic obstructive pulmonary disease (COPD) and asthma are
the most prevalent chronic respiratory diseases (CRDs) [1]. Globally,
COPD accounts for three million deaths annually, 90% of which are in
low- and middle-income countries (LMICs) [1,2]. Asthma is the most
common CRD, affecting 360 million people, it is the commonest
chronic disease of childhood and remains a burden to individuals,their families, and healthcare systems [1]. In LMICs, population-based
surveys have reported a high prevalence of respiratory symptoms
[35], obstructive and restrictive lung function [6,7], but low preva-
lence of diagnosed COPD [8] suggesting an unrecognised clinical
need. International Guideline recommendations are that asthma and
COPD require long term treatment and follow-up [9,10]. Knowing
the true lifetime CRD burden may potentially have profound implica-
tions for provision of respiratory health services. However, given the
scarcity of resources competing for healthcare priority there is a
pressing need to better document the impact of CRD’s on long-term
general morbidity. Few studies have reported and described the
Research in context
Evidence before this study
Multi-national studies report a high prevalence of abnormal
lung function in low- and middle-income countries (LMICs)
indicative of airflow obstruction (COPD, asthma) and restric-
tion. Very few studies have conducted longitudinal measure-
ment to investigate the natural history of lung function in
LMICs and impact on health-related quality of life (HRQoL).
Added value of this study
This study in rural Malawi showed that in a general population
of adults, the prevalence of COPD nearly doubled from 9.5% to
17.5% in 5 years. The rate of lung function decline in predomi-
nantly non-smoking adults is comparable with that reported
for smokers of 15 cigarettes a day in high income countries.
The respiratory symptoms and reductions in lung function
experienced by adult Malawians are associated with clinically
significant reductions in HRQoL.
Implications of all the available evidence
The high prevalence of COPD in sub-Saharan Africa adversely
affects quality of life and is, in part, a consequence of acceler-
ated lung function decline. The evidence justifies the imple-
mentation of sustainable initiatives for widespread diagnosis
and management of chronic respiratory diseases in sub-
Saharan Africa.
2 M.W. Njoroge et al. / EClinicalMedicine 41 (2021) 101166general health impact of diagnosed (and undiagnosed) asthma and
COPD in LMICs [11].
In Malawi, two studies have reported significant levels of abnor-
mal lung function with restrictive and obstructive lung function defi-
cits being present in 34.8% (95% CI: 31.7%, 38.0%) and 8.7% (7.0%,
10.7%) of rural adults, respectively, and 38.6% (34.4%, 42.8%) and 4.2%
(2.0%, 6.4%) of urban adults, respectively [5,12]. Whether these lung
function deficits arise from failure to attain the normal lung function
plateau in the third decade and/or from subsequent accelerated
decline of lung function remains to be ascertained. In addition, the
impact of these lung function deficits on general health status, peo-
ples’ everyday lives, and subsequent health service needs, is largely
unknown in this and other LMICs settings.
We report here the findings of a cohort study in rural Malawi [3]
in terms of annualised rate of change in lung function and associated
impact on health-related quality of life (HRQoL) to investigate the
natural history of abnormal lung function and its impact on HRQoL in
a LMIC.
2. Materials and methods
2.1. Setting and study design
Malawi is one of the world’s poorest countries (per capita GDP-
$300) and 83% of its 18 million inhabitants live in rural areas [13].
The prevalence of diagnosed COPD and asthma in Malawi is unknown
because lung function testing is unavailable out with research set-
tings. Chikwawa (population 360,000) is a predominantly rural dis-
trict of 4755 km2 in Southern Malawi.
We report the five year follow-up of a cohort of adult Malawians
recruited in 2014. The Chikwawa lung health cohort has been
described in detail elsewhere: Njoroge et al. [3]. In 2014 a commu-
nity-based prevalence survey, nested within a cookstove interventiontrial, was conducted in accordance with the Burden of Obstructive
Lung Disease (BOLD) protocol [3,14]. Participants were randomly
sampled from adults living in 50 villages in Chikwawa: [3,12] of the
3000 invited, 1481 participated. Non-participation was usually
because of inability to make contact, non-participants were younger
and more likely to be male [3,12].
Two rounds of follow-up in 2015 (n = 1090) and 2017 (n = 989)
investigated whether lung function decline was affected by the cook
stove intervention or personal air pollution exposures [15]. In 2019,
all the participants from 2014 were invited to take part in this five
year follow-up.
2.2. Ethical considerations
The study was approved by the Imperial College Research Ethics
Committee (17IC4272), Liverpool School of Tropical Medicine
Research Ethics Committee (19005) and the Malawi College of Med-
icine Research and Ethics Committee (COMREC, P.03/19/2617). All
participants provided written informed consent.
2.3. Data collection
Assessments in 2019 were almost identical to those in 2014, 2015
and 2017 and are described in detail elsewhere [3,12,15]. Interviewer
administered questionnaires covered respiratory symptoms, smoking
history, environmental exposures, demographics, socio-economic
status, and diagnosed respiratory disease [3,12].
Lung function (forced expiratory volume in one second [FEV1] and
forced vital capacity [FVC]) was measured by spirometry (NDD Easy-
One Spirometer, NDD Medizintechnik AG, Switzerland), performed
before and 15 min after 200 mg inhaled salbutamol via spacer. Stan-
dard contraindications for spirometry were applied and pregnant
women were not tested. The trained and certified spirometry techni-
cians received regular feedback on spirogram quality in accordance
with the BOLD protocol [14] and ATS/ERS recommendations [16]. The
quality of each spirometry trace was reviewed and scored based on
acceptability and repeatability criteria [14,16]. FEV1 and FVC readings
ranked A and B were analysed [16].
The 12item Short Form Survey (SF12) (administered in 2014)
and the Veterans RAND 12 item survey (VR12) (administered in
2019) were used to quantify HRQoL from responses to questions on
general health perceptions, physical functioning, role limitations due
to physical and emotional problems, bodily pain, energy and fatigue,
social functioning, and mental health [17,18]. The validated Brazier
SF6D algorithm was applied to obtain a summary preference-based
health utility measure (HRQoL utility score) that ranged from 0 (for
death) to 1 (full health) [19]. VR12 responses were mapped to the
utility scores from the Brazier SF6D algorithms to ensure that the
scores derived from the SF12 and VR12 were comparable. We also
assessed the distributional properties of scores obtained from SF12
and VR12 tools through the SF6D algorithms to confirm that they
were similar [20,21]. The 2015 and 2017 follow-ups did not include
HRQoL.
2.4. Statistical considerations
In 2014, a randomized age, sex-stratified sample was identified
from lists of adults living in the 50 cookstove trial villages [3,12]. The
baseline sample size estimate of 1200 [3,12], based on the BOLD pro-
tocol [14], resulted in a minimum sample size of 300 in any one age/
sex stratum (two age groups: 1839years,  40years) required to
approximate an expected prevalence of fixed airflow obstruction of
1025% with a precision 3.35.0% [12]. To compensate for the cook-
stove trial’s clustered design 1481 participants were recruited.
For the current follow-up, sample size estimates were informed
by reported rates of FEV1 decline in US, UK and Australian cohort
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detect an annual FEV1 change  17 ml to be 146 (73 men, 73 women)
per year with 90% power, and a = 0.05, and included 10% adjustment
for attrition and 20% for important covariates in the analysis. Given
the five years between 2014 and 2019, the expected difference would
be fivefold, we therefore anticipated a minimum of 730 participants
(365 men, 365 women) would suffice.
Global Lung Initiative 2012 reference values for African-American
ethnicity were used [25]. Absolute FEV1 and FVC were included as
continuous variables in longitudinal analyses. Each participant’s spi-
rometry was categorised into patterns consistent with clinical diag-
noses: ‘normal,’ pre-bronchodilator FEV1  lower limit of normal
(LLN), FVC  LLN, FEV1/FVC  LLN; ‘COPD,’ post-bronchodilator FEV1/
FVC < LLN with no/insignificant bronchodilator reversibility;
‘asthma,’ pre-bronchodilator FEV1/FVC < LLN and significant revers-
ibility (post-bronchodilator improvement in FEV1  12% and
 200 ml); and ‘restriction,’ post-bronchodilator FVC < LLN, FEV1/
FVC  LLN [9,10].
Primary outcome measures were lung function (FEV1, FVC) and
HRQoL score. Rate of change of FEV1, and FVC were expressed as ml/
year and z-score/year. Rate of change in HRQoL score associated with
changes in the lung function were also estimated. Clinical considera-
tions, analysis of variance and simple linear regression methods iden-
tified the following explanatory variables for inclusion in
multivariable analysis: follow-up time, age, height, BMI, sex, previous
TB diagnosis, smoking, years of schooling, clinical spirometry pat-
terns, reported respiratory diagnoses (any of asthma, emphysema,
chronic bronchitis, COPD).
Linear mixed-effects models were used to analyse lung function
using all the 2014 and 2019 data. To investigate associations with
rates of FEV1 and FVC, multiplicative terms were individually
included in models: time*diagnosed asthma, time*diagnosed COPD,Fig. 1. Participants in the various follow-up phtime*previous TB, time*smoking history, time*spirometry consistent
with asthma, time*spirometry consistent with COPD, time*restrictive
spirometry. Sensitivity analyses included those participants with
lung function from both 2014 and 2019. HRQoL data were only col-
lected in 2014 and 2019. Linear mixed-effects models with robust
standard errors were used to analyse HRQoL scores because of they
have an increasingly skewed distribution. Beta regression models
with their important explanatory variables were used to conduct sen-
sitivity analysis of HRQoL to assess validity of the mixed-effects
model with robust standard errors. In all mixed-effects models, ran-
dom effects were accounted for at the individual level whilst the
explanatory fixed-effects were selected sequentially with the opti-
mum model fit by likelihood ratio and deviance testing under maxi-
mum likelihood estimation. Statistical analysis was conducted using
R v3.6.0. All significance tests were two-tailed, with p < 0.05 consid-
ered significant.
2.5. Role of the funding source
The funder of the study had no role in the study design, data col-
lection, data analysis, data interpretation, or writing of the report.
MWN, PB, GD, AO, LN, and JR had full access to all the data in the
study. All the authors had final responsibility for the decision to sub-
mit for publication.
3. Results
Between July 2019 and August 2020, 1232 (83%) of the 1481 origi-
nal participants were assessed. We were unable to follow-up 249: 93
(6.3%) had died, 9 (0.6%) had moved away, 7 (0.5%) were working
away, and no information was available for 140 (9.5%). Fig. 1 outlines
participant numbers in each follow-up.ases of the Chikwawa lung health cohort.
Table 2
Changes in symptom prevalence, diagnosed respiratory disease and lung








203 (13.7%) 350 (28.4%)
Cough most days of the
month for  3 months
of the year, n (%)
167 (11.3%) 294 (23.8%)
Usually brings up
phlegm from chest, n
(%)
39 (2.6%) 128 (10.4%)
Wheezing/whistling in
chest in the past 12
months, n (%)
63 (4.3% 85 (6.9%)
Wheezing/whistling in
chest in the past 12
months in the absence
of a cold, n (%)
24 (1.6%) 60 (4.9%)
Shortness of breath
when hurrying on the
level or walking up a
slight hill, n (%)
23 (1.6%) 69 (5.6%)
Breathing problems
interfere with usual
daily activities, n (%)
44 (3.0%) 44 (3.6%)
Diagnosed lung disease
Diagnosed asthma, n (%) 51 (3.4%) 56 (4.5%)
Diagnosed COPD, n (%) 1 (0.1%) 11 (0.9%)
Diagnosed asthma,
emphysema, chronic
bronchitis, or COPD, n
(%)
59 (4.0%) 84 (6.8%)
Previous TB, n (%) 47 (3.2%) 87 (7.0%)
Spirometry (n = 886) (n = 1082)
FEV1 (ml); mean (SD) 2645 (658) 2279 (723)
4 M.W. Njoroge et al. / EClinicalMedicine 41 (2021) 101166Mean (SD) participant age in 2019 was 49.5 (17.0) years, 278
(23%) had ever smoked, and 724 (59%) were women (Table 1). A
greater proportion of the 2014 cohort participated in 2019 (n = 1232
(83%)) than in 2015 (n = 1090 (74%)) or 2017 (n = 989 (67%)). Compar-
ison of the 2014 characteristics of those participating or not partici-
pating in 2019 (supplement Table E1) indicated that those
participating in 2019 were older (mean difference [MD] (95% CI):
7.9 years (5.8, 9.9)), less educated (MD: 1.2 years, 0.7, 1.7), less likely
to have acceptable spirometry (percentage difference (95% CI): 12.1%
(5.5, 18.7%)), had reduced FEV1 (MD (95% CI): 3.71%, (0.02, 7.40%)),
and reduced HRQoL score (MD (95% CI): 0.03, (0.01, 0.05)). However,
participation in 2019 was not significantly associated with sex, smok-
ing history, respiratory symptoms, or diagnoses.
The number of participants providing acceptable spirometry in
2019 (n = 1082) was greater than in 2014 (n = 886), 2015
(n = 628) and 2017 (n = 571), while 675 participants had accept-
able spirometry in both 2014 and 2019 (Supplement Table E5).
Participants providing acceptable spirometry in 2019 were signifi-
cantly older, had more years of schooling and were less likely to
report coughing, but did not differ significantly for sex, smoking,
or symptoms of wheeze, breathlessness or sputum expectoration
when compared with participants with no/unacceptable spirome-
try, (Supplement Table E2).
3.1. Symptoms
There was an increase in reported respiratory symptoms between
2014 and 2019 (Table 2); the proportion difference (95% CI) for ‘any
respiratory symptom’ was 14.7% (11.6, 17.8%); ‘cough’ 12.5% (9.6,
15.5%); ‘sputum expectoration’ 7.8% (5.8, 9.7%); ‘wheezing’ 5.3% (3.7,
7.0%); ‘dyspnoea’ 4.0% (2.5, 5.6%). Participants also reported more
diagnosed asthma, emphysema, or COPD 2.8% (1.0, 4.6%) and previ-
ous TB 3.8% (2.1, 5.6%). Restricting analysis to participants providingTable 1





Women, n (%) 844 (57.0%) 724 (58.8%)
Age (years, mean (SD)) 43.9 (17.8) 49.5 (17.0)
Grouped age (years), n
(%)
< 39 685 (46.3%) 403 (32.7%)
4049 258 (17.4%) 268 (21.8%)
5059 217 (14.7%) 213 (17.3%)
6069 161 (10.9%) 167 (13.6%)
> 70 160 (10.8%) 181 (14.7%)
BMI (kg/m2), mean (SD)) 21.6 (3.46) 21.8 (3.93)
BMI, n (%)
Underweight (< 18.5) 182 (13.9%) 219 (17.8%)
Normal weight ( 18.5;
< 25.0)
950 (72.8%) 795 (64.4%)
Overweight ( 25.0;
< 30.0)
133 (10.2%) 161 (13.1%)
Obese ( 30.0) 40 (3.1%) 58 (4.7%)
Never smoked 1154 (77.9%) 954 (77.4)
Years of schooling com-
pleted, mean (SD)
4.21(4.09) 3.80(3.94)
Highest level of educa-
tion completed
None 485 (32.7%) 477 (38.7%)
Primary School 758 (51.2%) 576 (46.8%)
High School 232 (15.7%) 165 (13.4%)
College & University 4 (0.27%) 14 (1.14%)
Unknown 2 (0.14%) 0 (0.00%)
FVC (ml); mean (SD) 3283 (739) 2983 (835)
FEV1,%predicted; mean
(SD)
97.8% (16.8%) 91.8% (19.3%)
FVC,%predicted; mean
(SD)
101% (15.6%) 98.8% (19.8%)
FEV1/FVC; mean% (SD) 80.5% (8.5%) 76.1% (11.0%)
Obstruction
FEV1/FVC<LLN n (%)* 84 (9.5%) 189 (17.5%)
FEV1/FVC<0.70 n(%) 82 (9.3%) 232 (21.4%)
Mild: FEV180% pre-
dicted n (%)




26 (2.9%) 103 (9.5%)
Severe: 30%FEV1<50%
predicted n (%)
8 (0.9%) 17 (1.6%)
Very severe: FEV1<30%
predicted
1 (0.1%) 6 (0.6%)
Restriction
FVC<LLN n (%) 44 (5.0%) 91 (8.4%)
Spirometry clinical
pattern
Normal 702 (79.2%) 748 (68.2%)
COPD* 61 (6.9%) 134 (12.4%)
Asthma 23 (2.6%) 40 (3.7%)
Restriction 34 (3.8%) 52 (4.8%)
Unclassified not normal
spirometry pattern
66 (7.4%) 108 (10.0%)
* discrepancy reflect differences numbers for those with acceptable
post-bronchodilator spirometry and those with acceptable pre and post
bronchodilator spirometry.respiratory symptom data in both 2014 and 2019 made little differ-
ence to the magnitude of the observed differences (Supplement Table
E3).
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Comparison of spirometry data between 2014 and 2019 indicated
that the unadjusted annual rate of FEV1 decline was 73.4 ml/year
(95% CI): (61.0, 85.6; p < 0.0001) and for FVC 60.1 ml/year (46.0,
74.2; p < 0.0001) (supplement figure E1). When expressed as percent
predicted and z-scores (supplement Table E4), the rate of FEV1
decline exceeded that of FVC and that predicted by GLI-2012. These
rates of decline were reflected in the clinical patterns of lung function
such that in 2019 a higher proportion had spirometry consistent with
COPD (predominantly mild to moderate), however between 2014
and 2019 there was little difference in the proportion of participants
with spirometry consistent with asthma and pure restriction
(Table 2).
The lung function characteristics of participants with acceptable
spirometry in both 2014 and 2019 (n = 675) and for those with data
in 2014, 2015, 2017 and 2019 (n = 276) are presented in supplemen-
tary Tables E5, E6. In the 276 participants with acceptable spirometry
in all four study phases, FEV1 declined by 55.2 ml/year (95% CI: 34.6,
75.8; p < 0.0001) and FVC by 47.2 ml/year (22.6, 72.0; p < 0.0001).
In the mixed-effects regression model (Table 3) of all participants
with acceptable spirometry in 2014 and/or 2019 (model 1), adjusted
FEV1 declined by 53.4 ml/year (95% CI): (49.0, 57.8; p < 0.0001) and
FVC by 45.2 ml/year (39.2, 50.5; p < 0.0001). Reduced FEV1 and FVC
were significantly associated with age (FEV1 p < 0.001; FVC
p < 0.001), female sex (FEV1 p < 0.001; FVC p < 0.001), reducing
height (FEV1 p < 0.001; FVC p < 0.001), reducing BMI (FEV1
p < 0.001, FVC p = 0.004), but not smoking history (FEV1 p = 1; FVC
p = 0.803) or years of schooling (FEV1 p = 1; FVC p = 0.251). Reported
previous TB was associated with reduced FEV1(p < 0.001) and FVCTable 3

















































TB, Tuberculosis; BMI, body mass index; FVC, forced vital cap
FEV1 model: 88% of the variability of FEV1 accounted for in t
effects accounts for 70% of the variation.
FVC model: 86% of the variability of FVC accounted for in th
effects accounts for 62% of the variation.
$$ Models 1 include FEV1 and FVC data from all the particip
or 2019 (n = 1082).
££ Models 2, sensitivity analysis, include FEV1 and FVC dat
and 2019 (n = 675).(p < 0.001), whereas reported diagnosed asthma was associated with
reduced FEV1(p = 0.014) but not FVC(p = 0.453), a reported diagnosis
of emphysema (FEV1 p = 1; FVC p = 1), chronic bronchitis (FEV1 p = 1;
FVC p = 1), or COPD (FEV1 p = 0.830; FVC p = 0.485) was not associated
with FEV1 or FVC. When compared to those with normal lung func-
tion, spirometry patterns consistent with COPD or restriction were
associated with reduced FEV1(p< 0.001) and FVC (p< 0.001) and spi-
rometry consistent with asthma was associated with reduced
FEV1 (p < 0.001) but not FVC (p = 0.260). None of the included
interaction terms were significantly associated with FEV1 and FVC
indicating that rates of FEV1 and FVC decline were not associated
with diagnosed asthma (FEV1 p = 0.429; FVC p = 0.619), previous
TB (FEV1 p = 0.091; FVC p = 0.092), smoking history (FEV1
p = 0.910; FVC p = 0.108), or spirometry consistent with asthma
(FEV1 p = 0.731; FVC p = 0.160), COPD (FEV1 p = 0.900; FVC
p = 0.977), or restriction (FEV1 p = 0.502; FVC p = 0.531). Inclu-
sion of height squared and cookstove intervention allocation sta-
tus between 2014 and 2015 in the models revealed no
associations between the cookstove intervention or height
squared on FEV1, FVC or their rates of decline. A sensitivity analy-
sis of participants with acceptable spirometry in both 2014 and
2019 (model 2) indicated that adjusted FEV1 declined by 46.1 ml/
year (95% CI): (22.7, 69.0; p < 0.0001) and FVC by 42.4 ml/year
(37.7, 47.0; p < 0.0001). The parameter estimates for FEV1 and
FVC z-scores are presented in supplement Table E7.
3.3. Changes in health-related quality-of-life
Between 2014 and 2019 there was a significant decline in unad-
justed mean (SD) HRQoL utility score from 0.873 (0.133) to 0.790from participants in 2014 and 2019, statistically signifi-
FVC (ml)
2££ Model 1$$ Model 2££











































acity; FEV1, forced expiratory volume in 1 s.
he final mixed-effects regression model of which fixed-
e final mixed-effects regression model of which fixed-
ants with acceptable spirometry in 2014 (n = 886) and/
a from participants with acceptable spirometry in 2014
6 M.W. Njoroge et al. / EClinicalMedicine 41 (2021) 101166(0.116) (p < 0.0001) and the proportion reporting perfect health
(score of 1) declined from 39% (n = 582) to 2% (n = 23) (Supplement
Fig. E2). Reduced HRQoL in 2014 and 2019 was associated with
reported respiratory symptoms and previously diagnosed TB (Sup-
plement Table E8). Diagnosed emphysema, chronic bronchitis or
COPD was associated with reduced HRQoL in 2019 but not 2014,
diagnosed asthma was not associated with HRQoL (Table 4). Spirome-
try consistent with asthma was associated with reduced HRQoL (MD,
(95% CI): 0.080 (0.021, 0.131; p = 0.0029), as was spirometry consis-
tent with COPD (0.037, [0.020, 0.055, p < 0.0001]) and pure restric-
tion (0.055, [0.020, 0.089, p = 0.0003]) (Supplement Fig. E3).
In the mixed-effects regression model (Table 5) reduced HRQoL
was associated with time (p < 0.001), older age at baseline
(p < 0.001) and female sex (p < 0.001) but not years of schooling
(p = 0.807) or smoking (p = 0.085).
The symptoms of dyspnoea, wheeze, and cough were indepen-
dently associated with reduced HRQoL, with dyspnoea appearing to
be of greatest magnitude and cough the least. Reduced HRQoL was
associated with previous TB, but not diagnosed asthma, emphysema,
chronic bronchitis, or COPD. HRQoL was beneficially associated with
FEV1%predicted but not FVC. There were no significant interactions
between time and diagnosed conditions (diagnosed asthma
p = 0.714; diagnosed COPD = 0.221; previous TB p = 0.876) or spiro-
metric patterns (spirometry consistent with COPD p = 0.646; spirom-
etry consistent with asthma p = 0.409; spirometry consistent with
restriction p = 0.204).
4. Discussion
In this first longitudinal study of HRQoL in relation to ventilatory
function and chronic respiratory disease in sub-Saharan Africa, we
report adjusted annual rates of FEV1 and FVC decline of 53.4 ml/year
and 45.2 ml/year, respectively. More robust estimates of FEV1 and
FVC decline from those participating in both 2012 and 2019 were
46.1 ml/year and 42.4 ml/year, respectively. These rates of decline
were reflected in an increase in spirometry consistent with COPD
from 9.5% in 2014 to 17.5% in 2019. In the same period diagnosedTable 4




Any respiratory symptoms 0.805 (0
(n = 20
Cough  3 months of the year 0.811 (0
(n = 16
Usually brings up phlegm from chest 0.788 (0
(n = 39
Wheezing/whistling in chest in the past 12 months, n (%) 0.790 (0
(n = 63
Wheezing in the past 12 months in the absence of a cold 0.789 (0
(n = 24
Shortness of breath when hurrying on the level or walking up a slight hill. 0.759 (0
(n = 23
Breathing problems interfere with usual daily activities. 0.792 (0
(n = 44
Diagnosed lung disease
Diagnosed asthma 0.824 (0
(n = 51
Diagnosed, emphysema, chronic bronchitis, or COPD. 0.827 (0
(n = 59
Previous TB 0.806 (0
(n = 47COPD increased from 0.1 to 0.9%. There was no change in reported
diagnosis of asthma or in spirometry consistent with asthma or pure
restriction. The second main finding was that HRQoL was adversely
and independently associated with the symptoms of dyspnoea,
wheeze, and cough, previously diagnosed TB, and declining FEV1.
The annual rate of FEV1 decline of 4653 ml/year in this cohort is
greater than the ‘normal’ 2429 ml/year decline in healthy non-
smokers in high income countries (HICs), but similar to the
4055 ml/year decline in smokers of  15 cigarettes/day in HICs, and
the 53 ml/year reported in an accelerated FEV1 decline trajectory
group accounting for 48% of COPD in US and European cohorts
[22,26]. The cause(s) of the relatively rapid rate of FEV1 decline in
Malawian adults is unclear. Although comparable to smoking 15 ciga-
rettes/day in HICs, smoking is unlikely to underlie the observed
decline in the general Malawian because only 14% of participants cur-
rently smoked, with most smoking a few cigarettes a day. Previous
studies of this cohort have reported no association between lung
function (or rate of decline) and smoking status, cookstove interven-
tion and personal pollution exposure (PM2.5, CO) [15], similar to the
finding from our analysis. The relatively rapid rate of FEV1 decline
may be a result of frequent pulmonary infections consequent upon
genetic factors and/or dietary factors. Reduced FEV1 (but not rate of
decline) was associated with diagnosed asthma, previous TB, and spi-
rometry consistent with COPD, asthma, and restriction, suggesting
that the differences in lung function had occurred prior cohort set up
and were not a consequence of differential rates of FEV1 decline. This
finding is consistent with reports from HICs that reductions in FEV1
in later adult life observed in COPD and asthma are largely a conse-
quence of the tracking of suboptimal lung function from childhood
into adulthood [23,24,27].
The 2015 and 2017 follow-ups of this cohort reported an FEV1
decline of 30.9 ml/year and for FVC 38.3 ml/year, comparable with
rates reported in healthy non-smokers in HICs [15,22,26]. The most
likely explanation for the disparity between the 2015/7 and 2019 fol-
low-up (30.9 vs 53.4 ml/year) is the greater number participants with
acceptable spirometry in 2019 (n = 1082) compared with 2014
(n = 886), 2015 (n = 628) and 2017 (n = 571). It is likely that thend diagnosed respiratory diseases.
2014 2019
L scoremean, (SD) HRQOL scoremean, (SD)

























































































(n = 1145) < 0.001
Table 5
Robustly fit linear mixed effects modelling applied to HRQoL data from participants in 2014 and 2019.
HRQoL$$
Model A (Symptoms + spirometry clinical pattern) Model B (Symptoms + spirometry)








































































FEV1% predicted (per%) 0.0005
(0.000, 0.001)
0.034
FVC% predicted (per%) 0.0004
(0.0003, 0.001)
0.583





c Normal spirometry pattern.
& The spirometry pattern variable was added into the model instead of FEV1 variable.
$$ Models include HRQoL data from all the participants with acceptable spirometry (2014 n = 886, 2019 n = 1082).
M.W. Njoroge et al. / EClinicalMedicine 41 (2021) 101166 753.4 ml/year rate of decline reported here is an over-estimate result-
ing from participants providing spirometry in 2019, but not 2014,
who were older, current smokers and symptomatic. The analysis of
participants with acceptable spirometry in both 2014 and 2019 sup-
ports this notion, even so the rate of FEV1 decline of 46.1 ml/year is
still cause for concern. We did not observe the high rates of restric-
tion reported in urban Malawi (38.6%) and the 2014 baseline study of
this cohort (34.8%) [12], probably reflecting use of NHANES III predic-
tive equations for white Americans, whereas we used African-Ameri-
can GLI2012 predictive equations as recommended by ATS/ERS
[16].
Our findings that HRQoL is adversely and independently associ-
ated with age, female sex, respiratory symptoms (dyspnoea, wheeze,
cough), previous TB and declining FEV1 is consistent with other stud-
ies. A cross-sectional study of 50 Nigerian COPD patients reported
that respiratory HRQoL (St Georges Respiratory Questionnaire) is
adversely associated with age, female sex and dyspnoea, however
the Nigerian study reported no associations with wheeze, cough, or
FEV1, probably reflecting the smaller sample size than our study [28].
The present study differs from a report from BOLD that chronic bron-
chitis symptoms are associated with reduced HRQoL (SF-12) and the
impact is greater than for asthma or COPD [29]. In the current study,dyspnoea and wheeze symptoms were more strongly associated
with HRQoL than cough and phlegm symptoms and HRQoL was
adversely associated with spirometry consistent with asthma but not
COPD. These differences with BOLD may be a consequence of BOLD
being of cross-sectional design. Some cross-sectional studies in Africa
have reported reduced HRQoL in people with asthma and after TB
treatment [3032]. In the study reported here, a previous diagnosis
of TB and spirometry consistent with asthma and wheezing symp-
toms were adversely associated with HRQoL.
In the current study in Malawi, the differences in HRQoL indepen-
dently associated with dyspnoea, wheeze, previous TB and spirome-
try consistent with asthma or pure restriction exceeded the
minimally important difference (MID) reported for the SF-6D instru-
ment in longitudinal studies ((MID) (0.033, 95% CI: 0.0290.037))
and the MIDs reported for SF-6D in people with COPD (0.011, (SD
0.09)) [33].
The present study has strengths and limitations. Strengths include
the use of objective validated measures of ventilatory function and
HRQoL to follow-up a cohort of adults randomly identified in Malawi.
Although this cohort is largely representative of adults in rural
Malawi, a limitation is that nonparticipants in the original 2014 study
were younger and more likely to be male, anecdotally, younger men
8 M.W. Njoroge et al. / EClinicalMedicine 41 (2021) 101166in rural villages are more likely to seek work in towns/cities. The high
rate of follow-up of the cohort in 2019 increases confidence in the
generalizability of our findings to other similar settings. Spirometry
was performed in accordance with ERS/ATS guidelines [16], of high-
quality and enabled identification of COPD independent of partici-
pant report. Limitations include biases e.g., recall, social desirability,
consequent upon reliance on self-reports of symptoms, diagnoses,
and exposures by participants. Further limitations include the rela-
tively short 5 year follow-up and unavoidable use of UK tariffs
embedded within SF6D to generate HRQoL scores because appro-
priate and specific tariffs from relevant sub-Saharan settings have
not been published. The choice of tariff does matter, and country-spe-
cific tariffs should be used where available. The study was observa-
tional and consequently we can only report associations and cannot
exclude the possibility of residual confounding by factors associated
with participant selection and participation.
In conclusion in this cohort study of adults living in rural Malawi
the prevalence of COPD has increased by 12% a year and is associ-
ated with an annual rate of FEV1 decline greater than that reported in
HICs, combined with lung function deficits present before recruit-
ment that are likely to reflect early life influences and/or sequelae of
TB. Respiratory symptom burden and sub-optimal lung function are
independently associated with reduced HRQoL of magnitude greater
than the minimal important difference. These findings justify further
research into the aetiology, natural history, and most importantly
sustainable diagnosis and management of chronic respiratory dis-
eases in sub-Saharan Africa.Funding
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